C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2295-2300

  Molina, Rafael ^a   Jo, Judith ^a   Filella, Xavier ^a   Zanon, Gabriel ^a   Pahisa, Jaume ^a   Muñoz, Montserrat ^a   Farrus, Blanca ^a   Latre, Maria Luz ^a   Gimenez, Nuria ^a   Hage, Marta ^a   Estape, Jordi ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; C erbB 2; HER 2 neu; Oncoproteins; Prognosis; Tumor markers

Indexed keywords

ONCOPROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST DISEASE; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TISSUE LEVEL; TUMOR VOLUME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 9444225465     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bargman CJ, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal owth factor receptor related protein. Nature 319: 226-230, 1986.
2. Molina R, Ciocca R, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ and McGuire WL: Expression of HER-2/neu oncoprotein in human breast cancer. A comparison of immunohistochemical and western blot techniques. Anticancer Res 12: 1965-72, 1992.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keth DE, Levin WJ, Stuart SG, Udobe J, Ullrich A and Press MI: Studies of the HER-2 neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-12, 1989.
4. Tandon AK, Clark GM, Chamness GC, Ulrich A and McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-8, 1989.
5. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, Abelof MD and McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in-situ to invasive breast cancer. Human Pathol 23: 974-9, 1992.
6. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B and Hynes HE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238-43.
7. Marx D, Schauer A, and Reiche Ch: C-erbB-2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15-20, 1990.
8. Molina R, Filclla X, Segui MA, Climent MA, Perez-Picanol E, Alonso C, Jo J, Ojeda B, Tandon AK and Ballesta AM: Oncogenic proteins and prognostic correlations in breast cancer. In vivo 7: 585-90, 1993.
9. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L and McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncology 4: 599-605, 1992.
10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-82, 1987.
11. Zabrecky JR, Lam T, McKenzie SJ and Carney W: The extracellular domain of p185 neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 266: 1716-20, 1991.
12. Pupa SM, Menard S, Morelli D, Pozzi 13. De Palo G and Colnaghi MI: The extracellular domain of the c-erb B-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-23, 1993.
13. McKenzie SJ, De Sombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM and Bast RC: Serum levels of HER-2/neu (C-erbB 2) correlate with overexpression of p184 neu in human ovarian cancer. Cancer 71: 3942-6, 1993.
14. Narita T, Funahashi H, Satoh Y and Takagi H: C-erbB-2 in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97-102, 1992.
15. International Union Against Cancer (UICC): TNM classification of malignant tumours. Hermanek P, Sohen LH eds., 4 ed. Berlin: Springer Verlag, 1987.
16. Cohen JA, Weiner DB and More KF: Expression pattern of the neu (NGL) genencoded growth factor receptor protein (p185 neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4: 81-88, 1989.
17. Tsuda DJ, Battifora H, Yokota J, Yamamoto T and Cline MJ: Association of multiple copies of the c-erb B-2 oncogene with spread of breast cancer. Cancer Res 47: 6123-5, 1987.
18. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS and Altman DG: Immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448-52, 1988.
19. Zhou DJ, Ahauja H and Clinc MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105-108, 1989.
20. Paik S, Hazan Z, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger JI Lippman ME and King CR: Pathological findings from the National Surgical Adjuvant Breast Projects (protocol B-06): prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncology 8: 103-12, 1990.
21. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A and Balague A: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 36: 251-4, 1990.
22. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, Jo J and Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 37: 1379-83, 1991.
23. Molina R, Jo J, Pilella X, Bruix J, Gimenez N, Castells A, Hague M and Ballesta AM: Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and nonmalignant diseases. Tumor Biol 1995 (In press).
24. Cases A, Pilella X, Molina R, Ballesta AM, Lopez-Revert J and Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 37: 1379-83, 1991.
25. Filella X, Molina R, Jo J, Bedini JL, Joseph J and Ballesta AM: Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant diseases. Bull Cancer 79: 271-7, 1992.
26. Ritts RE, Del Villano BC, Go VLW, Heberman RB, Klug TL and Zurawski VR: Initial clinical evaluation of an immunoradiometric assay for CA 19.9 using the NCI serum bank. Int J Cancer 33: 339-45, 1984.
27. Colomer R, Ruibal A and Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-81, 1989.
28. Molina R and Ballesta AM: Evaluation of several tumor markers (MCA. CA 15.3, BCM and CA 549) in tissue and serum of patients with breast cancer. Ceriani RL, ed. Breast epithelial antigens. Molecular Biology to clinical applications. Plenum Press. New York 1991: 161-8.
29. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M and Ballesta AM: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Br Cancer Res and Treatment 36: 41-48, 1995.